Company / Cash per Share
Corvus Pharmaceuticals, Inc. Cash per Share History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$0.14
FY2024
5-year range
$0.14 / $1.52
FY2020-FY2024
Trend
-45.5%
vs FY2023
Sector context
#198 of 207
Health Care
What the data says
Among 207 Health Care companies, Corvus Pharmaceuticals, Inc. is in the bottom 4% for cash per share. Cash per Share has declined for 3 consecutive years, from $1.52 in FY2021 to $0.14 in FY2024.
Based on SEC 10-K filings.
0.14 in FY2024 with a 5-year CAGR of -4.0%.
Declined from $0.28 to $0.14 over the past 2 years.
Health Care sector context is included.
Cash per Share over time
Growth rates
- 3-Year CAGR
- -54.4%
- 5-Year CAGR
- -4.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 207This company $0.14 Sector average $67.39
▼
-99.8% below sector average
Key checks
Key Insights
- Corvus Pharmaceuticals, Inc.'s cash per share has declined for 3 consecutive years.
- In FY2024, cash per share decreased 45.5% year-over-year.
- Ranks #198 out of 207 companies in the Health Care sector.
- Peak cash per share was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.14 | -45.5% |
| FY2023 | $0.26 | -7.0% |
| FY2022 | $0.28 | -81.4% |
| FY2021 | $1.52 | +171.6% |
| FY2020 | $0.56 | +217.9% |
| FY2019 | $0.18 | -87.7% |
| FY2018 | $1.42 | -35.3% |
| FY2017 | $2.20 | +572.3% |
| FY2016 | $0.33 | -97.0% |
| FY2015 | $10.99 | -85.1% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026